Your session is about to expire
← Back to Search
Nicotinic Acetylcholine Receptor Partial Agonist
Cohort 3 for Smoking Cessation
Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
Summary
This study will evaluate the steady-state pharmacokinetics, safety and tolerability of a varenicline patch applied once daily to the skin for 14 days.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment2 Interventions
Group II: Cohort 3Experimental Treatment2 Interventions
Group III: Cohort 2Experimental Treatment2 Interventions
Group IV: Cohort 1Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Varenicline
FDA approved
placebo patch
2007
Completed Phase 4
~2100
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
PfizerLead Sponsor
4,642 Previous Clinical Trials
17,743,018 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,530 Previous Clinical Trials
14,914,357 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger